Core Viewpoint - XuanZhu Bio-B (02575) shares surged over 20%, reaching a new high of HKD 93.05, driven by the inclusion of its innovative drug XuanYueNing in the national basic medical insurance drug list, enhancing affordability and accessibility for patients [1] Group 1: Company Developments - The recent announcement regarding XuanYueNing's inclusion in the national basic medical insurance drug list is expected to positively impact the company's long-term operational development by promoting market penetration and increasing sales scale [1] - The company is set to achieve significant milestones with two new oncology drugs expected to be approved by 2025, which will solidify its innovative value in the pharmaceutical industry [1] Group 2: Product Insights - The oncology drug Piroxil is strategically positioned in the breast cancer market with a differentiated indication, while Dirocizumab offers high intracranial penetration and over 91% IC-ORR, addressing a gap in brain metastasis treatment [1] - Together with Anailaz Sodium, these products form a "three-horsepower" commercial framework that lays a solid foundation for the company's long-term growth [1]
轩竹生物-B涨超20%再破顶 轩悦宁进入医保目录 两款肿瘤产品年内密集获批